The Board of Scandinavian Clinical Nutrition AB (SCN) today decided to propose an Extraordinary General Meeting to offer the holders of the convertible bonds issued in May 2008 and one of the company’s major creditors to buy shares in Scandivir AB through a settlement of claims.

As previously communicated, SCN has initiated an extensive program designed to reduce the company’s costs and risks compared to previous years, to counter the current financial crisis and prepare the company for future challenges. An important part of the program is to reduce the company’s debt load. If all the creditors accept the offer, it will decrease SCN’s debt load and increase the capital base substantially.

The notice in full to the Extraordinary General Meeting can be found in the attached pdf file, which also will be available on the company’s website from March 17 onwards. The pdf file also contains an attendance form and a proxy form.

For more information, please contact:

Ulf Söderberg, CEO,, +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board,, +47 924 99 360

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess ( and NGM Equity ( more information, please visit


Documents & Links